PFE Stock Recent News
PFE LATEST HEADLINES
Pfizer hiked its full-year adjusted profit guidance on its cost cuts and strong business performance this year. The company also reported second-quarter results that topped Wall Street's estimates for the period.
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) reported financial results for the second quarter of 2025 and reaffirmed its 2025 Revenue guidance while raising guidance(1) for Adjusted(2) diluted EPS. EXECUTIVE COMMENTARY Dr. Albert Bourla, Chairman and CEO of Pfizer: “Pfizer had another strong quarter of focused execution and we're pleased with our progress in advancing our R&D pipeline, driving our commercial performance and expanding our margins. We continue to strengthen our company.
The healthcare sector has long been a favorite for income investors -- and for good reason. Many healthcare stocks offer attractive dividend yields.
Over the last century, no asset class has generated a higher average annualized return for investors than stocks. Though there are countless way for investors to put their money to work on Wall Street, few have been as historically successful as buying and holding high-quality dividend stocks.
Are you looking to put a sizable chunk of cash to work generating investment income? Whether you intend to live on this income or reinvest it to bolster your portfolio's overall growth, there are several great dividend-paying options out there right now.
The final trades of the day with CNBC's Melissa Lee and the "Fast Money" traders.
Let's look at five pharma and biotech companies, PFE, LLY, AMGN, GILD and NVO, which are scheduled to release their second-quarter 2025 results this week.
Shares of Pfizer ( NYSE: PFE ) lost 6.50% over the past month, bringing the stock's year-to-date loss to 11.31%.
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Pfizer's strong EPS surprise streak and positive earnings revisions are encouraging, but patent cliff risks remain a major concern for future growth. Valuation appears attractive with ratios below sector medians and Wall Street seeing significant upside, yet EPS stagnation tempers enthusiasm. Despite potential for another earnings beat, a miss could trigger a selloff, while the 7.3% dividend yield offers defensive appeal amid market uncertainty.